Wow. Apparently some journalists are still working on Saturday despite cutbacks with reporters in that industry too.
Medical News Today reports that GSK received good news from the European Medical Agency's Committee for Medicinal Products for Human Use (CHMP). CHMP provided market authorization for Tyverb (lapatinib) for new indication in hormone receptor positive breast cancer patients - YES - a new indication.
The committe also issued a conditional approval for Votrient (pazopanib) for the first line treatment of renal cell cancer (RCC). As part of the conditions of the conditional marketing authorisation for pazopanib, GSK will be required to provide further data comparing pazopanib with sunitinib. This study is ongoing.
MNT also reported that Bayer and Regeneron announced positive results for VEGF Trap-Eye in a phase II study for treatment of Diabetic Macular Edema (DME).
Posted by Bruce Lehr Feb 20, 2010